How Has COVID-19 Stalled Drug Development
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmaceutical companies (view full video here). In this portion, Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), and Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), discuss how the pandemic has stalled some drug development efforts.
This website uses cookies to ensure you get the best experience on our website. Learn more